Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial

Background Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. Objective To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. Animals Forty‐nine client‐owned dogs with CKD. Methods Dogs were randomized to benazepril (0.25 to 0.5, and 0.38 (0.12–1.19) with P = .080 for initial UPC >0.5 plus plasma creatinine ≤440 μmol/L. Proteinuria, assessed from the UPC, was significantly (P = .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events. Conclusions and Clinical Relevance Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time.